Latest Commentary

Jardiance and its CV data? They're no knockout punch for stalwart Januvia, Merck says

LONDON--Late last month, partners Eli Lilly and Boehringer Ingelheim announced that their SGLT2 diabetes med, Jardiance, had gone where no others had gone before. While its rivals had always either increased the risk of cardiovascular events or, at best, had no effect, the newcomer showed it could actually lower the risk of heart attack, stroke and death from cardiovascular causes.

Who should Allergan buy next? We asked, you answered

Serial buyer Allergan is getting ready to head back to the bargaining table, and there's plenty of buzz about who its next target will be. Who should it be, though, as far as FiercePharma readers are concerned? That's the question we posed last Tuesday, and since then, more than 500 of you have weighed in. 

Who should be next on Allergan's buyout list? We want your votes

Allergan has been on quite the buyout spree lately, and with $40.5 billion coming in from Teva in exchange for its generics unit, it's about to settle some debt and get back to the dealmaking table. Who's next on CEO Brent Saunders' list, though, is anyone's guess, and we want to know what you think.

Teva's recent history gives Mylan chairman plenty of anti-buyout zingers

On Monday, Mylan slapped Teva with a laundry list of reasons it wasn't interested in a tie-up. But for Mylan, the problems with a get-together go beyond the business--and Chairman Robert Coury said as much before the Israeli drugmaker came forth with its $40 billion bid.

Indivior CEO looks beyond 2015 after troubled Reckitt pharma unit's spinoff

It's new year, new company for Reckitt Benckiser's pharma unit, spun off into Indivior last week. And while 2015 might not be the easiest for the newly minted drugmaker, CEO Shaun Thaxter says investors have much to look forward to a little further down the line.

Get out your binoculars for FiercePharma's traditional holiday trend-spotting

As surely as Linus and Lucy's jazz theme plays in shops decorated with Santa's and garland, and blue-and-white-wrapped chocolates and menorah candles appear on store shelves; as surely as calendar pages flutter into the trash, FiercePharma peers into the murky future to predict which headlines we'll be writing next year.

Pfizer believes a dose of confidence will help it sell biosimilars

As drug prices climb and expensive newcomers inspire payers to get creative to contain costs, a window is widening for meds that can drive efficiency for healthcare systems and address consumers' needs. That's where biosimilars come in--or so Pfizer figures.

We publish, you pick: FiercePharma's 10 best-read stories of 2014

In pharma, here are the top 10 news stories of the year so far, based on web traffic.

Who are the stars of personalized meds? Roche, Novartis and J&J

Targeted drugs, personalized medicine, stratified therapy--whatever you call it, using biomarkers to identify particular patients for particular drugs has been hailed as a boon for patients and a savvy strategy for pharma.

Takeda scrambles to fix glitches in Contrave direct-delivery launch

Takeda Pharmaceuticals saw a problem with recent obesity drug launches: Cost. Private insurers and public payers were refusing coverage--or foisting big copays onto patients--dragging down new drugs marketed by Vivus and Eisai.